Hints and tips:
....; Teva Pharmaceuticals USA; Actavis Holdco U.S., Inc.; Actavis Pharma, Inc.; Ascend Laboratories, LLC; Apotex Corp.; Dr....
...Actavis acquired Allergan, which makes the Botox cosmetic, last year and adopted its name after the deal closed....
...Teva of Israel is close to completing its $40bn takeover of Allergan’s Actavis generics division and Mylan of the US last month agreed to buy Meda of Sweden for $7.2bn....
...The tie-up with Actavis also paved the way for further dealmaking....
...So could Mr Saunders be about to put on his laboratory coat and buy a company such as Biogen or AbbVie? “It’s possible....
...But Allergan’s combination last year with Actavis — itself newly enlarged through a dizzying series of deals — created a company that fitted his two main criteria....
...Others include Actavis, which bought Allergan, the maker of Botox, last year for $66bn and has since adopted the Allergan name....
...Teva’s pursuit has been complicated by the fact that Mylan is officially based in the Netherlands following its acquisition last year of overseas assets from Abbott Laboratories, a rival US group, in a so-called...
...Most recently it bought Botox maker Allergan for $70bn and ditched the company’s previous name, Actavis....
...He says that of the world’s top 20 best-selling drugs, just “two or three were truly discovered in the laboratory”, with the rest being new takes on existing compounds....
...The frenzy began when Actavis bought Forest Laboratories for $25bn early last year and has continued ever since, involving almost every big drugmaker and many supporting actors from the biotech and medical...
...For Mr Pearson, modern drugmaking is stuck in the past, clinging to a postwar business model where armies of white-coated scientists toil away in laboratories....
...resisted Teva’s advances, preferring instead to pursue its own $33bn hostile bid for Perrigo, a Dublin-based generic drugmaker, just two months after completing a $5.3bn acquisition of products from Abbott Laboratories...
...Both Teva and Mylan are big rivals of Actavis, whose prolific M&A activity over the past year has catapulted it into the top tier of global pharmaceuticals manufacturers....
...It bought Watson Pharmaceuticals for $6bn (2012), Ireland-domiciled Warner Chilcott for $9bn (2013) and Forest Laboratories for $25bn (2014)....
...Actavis had stopped selling the pill and told doctors to move patients to a newer version, Namenda XR....
...The company had five drug applications approved by the US regulator last year, most of which originated in its own laboratories, he says....
...Laboratories in February, and is now heavily linked with a bid for Allergan of the US....
...US pharmaceuticals group Mylan has agreed to pay $5.3bn for the generic drugs business of Abbott Laboratories, in another sign of the deal mania sweeping the healthcare sector....
...Actavis, the highly acquisitive Dublin-based drugs maker, has agreed to buy New York’s Forest Laboratories for $25bn, its biggest purchase to date....
...So it makes sense that Actavis shares rose 8 per cent on news that it would pay $7bn in cash and issue $18.5bn worth of its shares (a 51 per cent increase in the share count) to buy Forest Laboratories....
...The $25bn purchase of Forest Laboratories, announced on Tuesday, is by far the largest transaction he has overseen so far....
...Partly because his four-year campaign of pressure on the drugmaker Forest Laboratories came to lucrative fruition in a $25bn sale to Actavis....
...There probably are,” says Brent Saunders, the chief executive of Actavis who engineered the biggest takeover of 2014 — the $70.5bn acquisition of Botox maker Allergan....
...Analysts at Goldman said the acquisitive Dublin-based company would see a “substantial” sales and profit improvement if it is able to complete its $25bn buyout of New York’s Forest Laboratories....
International Edition